AFREZZA® - A First-in-class Ultra Rapid-Acting Insulin
AFREZZA® (pronounced uh-FREZZ-uh) is a first-in-class, ultra rapid-acting mealtime insulin therapy being developed to improve glycemic control in adults with Type 1 and Type 2 diabetes mellitus. It is a drug-device combination product, consisting of AFREZZA Inhalation Powder single use dose cartridges, and the small, discreet and easy-to-use AFREZZA inhaler.
Administered at the start of a meal, AFREZZA dissolves immediately upon inhalation and delivers insulin quickly to the blood stream. Peak insulin levels are achieved within 12 to 15 minutes of administration, mimicking the release of mealtime insulin observed in healthy individuals.
The extensive and ongoing AFREZZA clinical program, which has involved more than 6,500 adult patients and compared AFREZZA to the standard of care insulin treatment, has demonstrated the following outcomes:
Proven reductions in HbA1c
A reduced risk of hypoglycemia vs. rapid-acting analogs
Less weight gain vs. rapid-acting analogs
Injection-free insulin delivery
In clinical trials of up to two years duration in Type 1 and Type 2 adult patients with diabetes, observed changes in lung function were small, did not progress and resolved when AFREZZA treatment was discontinued. The most common respiratory side effect experienced with AFREZZA in trials was a mild, transient, non-productive cough. Discontinuation due to cough was uncommon.
We believe that AFREZZA is a unique diabetes therapy with the potential to change the way this disease is treated by offering significant benefits to the growing population of patients with diabetes. AFREZZA addresses several limitations of current mealtime insulin treatments by offering glycemic control with lower risk of hypoglycemia, less weight gain and an alternative to injections.